Skip to main content
. 2016 Jul 18;16:107. doi: 10.1186/s12883-016-0627-y

Table 2.

Treatment and complications

Pneumonia at the SU
No Yes Univariate analysis Multivariate analysis
Treatment and complications 56447 (94.8 %) 3111 (5.2 %) P 5–95 % CI OR p
iv-Thrombolytic therapy¸ n (%) 7822 (13.9) 685 (22) <0.001
Iv Insulin¸ n (%) 464 (0.8) 131 (4.2) <0.001 1.22–1.98 1.55 <0.001
Iv Antihypertensive drugs, n (%) 2163 (3.8) 379 (12.2) <0.001 1.22–1.62 1.41 <0.001
Lipid lowering drugs, n (%) 28657 (63.8) 1213 (50.2) <0.001
Antiplatelet drugs, n (%) 45408 (80.4) 2279 (73.3) <0.001
Endotracheal intubation, n (%) 400 (0.7) 143 (4.6) <0.001
Nasogastric tube, n (%) 3864 (6.8) 1461 (47) <0.001 2.84–3.47 3.14 <0.001
Percutaneous gastrostomy, n (%) 286 (0.5) 175 (5.6 % <0.001 2.02–3.14 2.52 <0.001
Urinary catheter, n (%) 15382 (27.3) 2471 (79.4) <0.001 2.15–2.72 2.42 <0.001
Physiotherapy, n (%) 39207 (69.5) 2741 (88.1) <0.001
NIHSS at discharge from SU, median, interquartile range 2 (0, 5) 13 (6, 20) <0.001
Difference NIHSS admission – discharge, median, interquartile 1 (0, 3) 0 (−1, 3) <0.001
Speech therapy, n (%) 29020 (51.4) 2337 (75.1) <0.001 1.23–1.5 1.36 <0.001
Progressive stroke, n (%) 1447 (2.6) 296 (9.5) <0.001 1.47–2.01 1.72 <0.001
Recurrent stroke, n (%) 425 (0.8) 82 (2.6) <0.001 1.25–2.25 1.68 <0.001
SICH, n (%) 552 (1.0) 151 (4.9) <0.001
Epileptic seizure, n (%) 451 (0.8) 119 (3.8) <0.001 1.36–2.23 1.74 <0.001
Brain edema, n (%) 550 (1.0) 222 (7.1) <0.001 1.29–1–9 1.56 <0.001
Septicemia, n (%) 141 (0.2) 87 (2.8) <0.001 2.47–4.83 3.45 <0.001
Urinary tract infection, n (%) 2042 (3.6) 444 (14.3) <0.001 1.1–1.42 1.25 <0.001
Heart failure, n (%) 661 (1.2) 328 (10.5) <0.001 2.16–3.04 2.56 <0.001
Pulmonary embolism, n (%) 85 (0.2) 42 (1.4) <0.001
Arrhythmia, n (%) 1187 (2.1) 378 (12.2) <0.001 1.79–2.43 2.08 <0.001

NIHSS denotes National Institute of Health Stoke Scale, SICH symptomatic intracranial hemorrhage. Numbers are n and % or median and interquartile range, as indicated. OR denotes odds ratio, CI confidence interval. Multivariate analysis is continued from Table 1